| Quality assessment | No of patients | Effect | Quality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Gemcitabine, docetaxel | Control | Relative (95% CI) | Absolute | |
| Overall survival | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | N=29 | - | Median OS = 7.7 months | ⊕○○○ VERY LOW | |
| Progression-free survival | |||||||||||
| 0 | No evidence available | ||||||||||
| Overall tumour response (assessed with: ECOG criteria) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 5/27 (18.5%) | - | - | - | ⊕○○○ VERY LOW |
| Neutropenic fever | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 2/29 (6.9%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Thrombocytopenia (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 4/29 (13.8%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Anaemia (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 8/29 (27.6%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Granulocytopenia (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | serious2 | serious3 | none | 10/29 (34.5%) | - | - | - | ⊕○○○ VERY LOW |
| Treatment-related mortality | |||||||||||
| 0 | No evidence available | ||||||||||
| Health-related quality of life | |||||||||||
| 0 | No evidence available | ||||||||||
Adjuvant and neoadjuvant chemotherapy considered as first-line chemotherapy (proportion of sample not stated);
Small sample size / low number of events limit the precision of this outcome
From: 5, Managing locally advanced or metastatic bladder cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.